Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for PRGO.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 -388.90M
March 31, 2026 -45.30M
December 31, 2025 -54.40M
September 30, 2025 -50.30M
June 30, 2025 -54.00M
March 31, 2025 -61.80M
December 31, 2024 -1.154B
September 30, 2024 653.30M
June 30, 2024 -49.80M
March 31, 2024 -60.40M
December 31, 2023 -44.60M
September 30, 2023 -43.30M
June 30, 2023 -48.60M
March 31, 2023 -50.70M
December 31, 2022 -42.50M
September 30, 2022 -43.00M
June 30, 2022 559.00M
March 31, 2022 -51.90M
December 31, 2021 -58.00M
September 30, 2021 -36.30M
June 30, 2021 -41.10M
March 31, 2021 -43.30M
December 31, 2020 -201.40M
September 30, 2020 -646.50M
June 30, 2020 602.10M
Date Value
March 31, 2020 64.70M
December 31, 2019 -31.50M
September 30, 2019 -144.90M
June 30, 2019 219.80M
March 31, 2019 -41.60M
December 31, 2018 -34.30M
September 30, 2018 -175.40M
June 30, 2018 -199.60M
March 31, 2018 -162.60M
December 31, 2017 -378.90M
September 30, 2017 -172.50M
June 30, 2017 -2.412B
March 31, 2017 -36.80M
December 31, 2016 -34.60M
September 30, 2016 -539.60M
June 30, 2016 -131.90M
March 31, 2016 437.40M
December 31, 2015 1.136B
September 30, 2015 44.30M
June 30, 2015 -955.20M
March 31, 2015 -31.60M
June 30, 2014 -46.90M
March 31, 2014 -47.50M
December 31, 2013 1.126B
September 30, 2013 -4.00M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Avadel Pharmaceuticals Plc 2.636M
Jazz Pharmaceuticals Plc -994.50M
GH Research Plc 111.51M
Cosmo NV --
Viatris, Inc. -1.243B